Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (15045)	2/14/1998 12:01:00 AM
From: Machaon	Respond to of 32384

<< UPCOMING EVENTS: Upcoming events for Ligand include: >> Thanks for posting the list. I'm going to print it out, and keep it close. Most stocks choke on bad news. It seems like the LGND stock chokes on an overabundance of good news. Sooner, or later, this puppy is going to jump. I just want to be there when it happens. Regards, Bob

To: Vector1 who wrote (15045)	2/14/1998 4:34:00 AM
From: Henry Niman	Respond to of 32384

The list is impressive. I suspect that the Droloxifene for breast cancer will not happen, but there will be more INDs for diabetes from LLY and AGN as well as the start of a US diabetes trial by LLY.

To: Vector1 who wrote (15045)	2/17/1998 8:43:00 AM
From: Henry Niman	Respond to of 32384

Vector1, Thanks for the RS info. I have heard a few more details and a couple of points I found interesting was their 1999 earnings projections, which they now have at the break even point. I'm not sure what their prior estimate was, but I suspect that breaking even for 1999 is a marked improvement. I also heard that as far as signal transduction is concerned, LGND's program is considered the most comprehensive in the Pharmaceutical (not Biotech) Sector. I consider the comment both quite complimentary as well as accurate. The report also listed the propriety areas that LGND excelled in, which included Retinoids, SERMs, Orphan Receptors, STATs, and the GLYC technology. The report did caution that to really move the price forward, LGND had to show positive clinicals in one of the major cancer markets, but such data may be forthcoming very soon (I believe that Targretin prostate and ovarian Phase II data will be released short term).

To: Vector1 who wrote (15045)	2/17/1998 9:26:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

V1, It looks like the positive earnings estimates are affecting Zacks. I just looked at their Feb 7 report (I think that the RS report is dated Feb 13) and Zack's gave LGND a STRONG BUY! I can't recall ever seeing such a strong rating from Zack's for LGND.

To: Vector1 who wrote (15045)	2/17/1998 9:37:00 AM
From: Henry Niman	Respond to of 32384

V1, To give you an idea of how unusual a STRONG BUY rec is for Zack's to give to a Biotech, check out SANG. It is ranked #2 among the Biotechs because there are six brokerage houses covering it (based on Zack's Feb 8 report) and all 6 call it a STRONG BUY. However, Zack's gives it a STRONG SELL! In any event, Buyers are out early on LGND. Bid is already up to 14 1/2 and ask is 14 5/8. I suspect many are pleased with RS latest report on LGND.